Announcements Trials
Browse Landscape

Phase

Phase 2 6Phase 3 5Phase 1/2 3Phase 1 1

Status

Completed 5

Sponsor Class

INDUSTRY 4OTHER 1

Study Type

Interventional 5

Sponsor

Cancer Type

Gastrointestinal 3Tumor-Agnostic 1Thoracic 1

Conditions

Pancreatic Neoplasms 2Small Cell Lung Carcinoma 1Neoplasms 1Metastatic Adenocarcinoma of the Pancreas 1

Interventions

Cisplatin 186Carboplatin 181Paclitaxel 175Docetaxel 144Cyclophosphamide 129Dexamethasone 117pembrolizumab 106Doxorubicin 103Bevacizumab 103Gemcitabine 102Rituximab 96Prednisone 87Fluorouracil 86Pemetrexed 81Radiotherapy 77Vincristine 71Etoposide 71Capecitabine 69Nivolumab 68Trastuzumab 67Leucovorin 64Cytarabine 57Methotrexate 52Oxaliplatin 49atezolizumab 47Lenalidomide 43Ipilimumab 40Filgrastim 40Bortezomib 39Sorafenib 38

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

5 trials
RecentStart dateEnrollment
Phase 3 × Has results × irinotecan sucrosofate × Clear all
NCT04083235 2026-04-20

NAPOLI 3

Ipsen

Phase 3 Completed
770 enrolled 13 charts 1 FDA
Gastrointestinal

Metastatic Adenocarcinoma of the Pancreas

NCT03088813 2025-02-19

RESILIENT

Ipsen

Phase 3 Completed
491 enrolled 24 charts
Thoracic

Small Cell Lung Carcinoma

NCT01926197 2022-10-28

Phase 3 Study of FOLFIRINOX (mFFX) +/- SBRT in Locally Advanced Pancreatic Cancer

Stanford University

Phase 3 Completed
27 enrolled 15 charts
Gastrointestinal

Pancreatic Neoplasms

NCT03665441 2022-10-18

Trybeca-1

ERYtech Pharma

Phase 3 Completed
512 enrolled 19 charts
Tumor-Agnostic

Neoplasms

NCT01494506 2016-06-17

NAPOLI-1

Merrimack Pharmaceuticals

Phase 3 Completed
417 enrolled 20 charts
Gastrointestinal

Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡